Leading health technology (HealthTech) company Intelligencia AI recently named leading pharmaceutical industry figure Névine Zariffa as chair of its Scientific Advisory Board. The formalization of its Scientific Advisory Committee by Intelligencia AI™ demonstrates the latter’s investment in growth, and signals the start of a new chapter of maturity for this company founded in 2017 in New York.
With its deeply curated scientific data and artificial intelligence algorithms, Intelligencia AI is transforming the biopharmaceutical industry’s approach to assessing the probability of technical and regulatory success (PTRS) of drugs in development , to improve the efficiency of clinical development and commercial decisions.
In her new role, Ms. Zariffa will provide strategic advice on the company’s product development roadmap, while orchestrating and coordinating the activities of the other accomplished leaders appointed to the Scientific Advisory Board.
“ Ms. Zariffa’s in-depth expertise in clinical development, and her investigative approach to industry needs and innovation, make her the ideal candidate for this new role. She has been a trusted advisor since 2021 and will continue to support our growth,” said Dimitrios Skaltsas, CEO and co-founder of the company.
With a 25-year career in the pharmaceutical industry in the areas of biostatistics and data science, Ms. Zariffa brings to Intelligencia AI extensive experience in all phases of drug development. Most recently, she served as Senior Vice President of Biometrics and Information Sciences at AstraZeneca (AZ), where she was a key governance member and guided executives in their investment decisions in R&D. Also at AZ, she also led the Enterprise Data and Analytics Program. During her career, she has made major contributions to the development of more than 200 drug projects in various therapeutic areas. Ms. Zariffa currently serves as a strategic advisor to selected clients and continues to shape large data-driven scientific consortia.
“ I am honored to find myself at the head of a group of very talented scientific advisors. We will continue to work together to increase the impact of Intelligence AI on the industry. The company’s rigorous approach to creating fundamental data and algorithms makes it a unique partner for anyone who believes there is still work to be done to accelerate patient access to new medicines.” , said Ms. Zariffa.
SOURCE: Businesswire